IN2014MN01420A - - Google Patents

Info

Publication number
IN2014MN01420A
IN2014MN01420A IN1420MUN2014A IN2014MN01420A IN 2014MN01420 A IN2014MN01420 A IN 2014MN01420A IN 1420MUN2014 A IN1420MUN2014 A IN 1420MUN2014A IN 2014MN01420 A IN2014MN01420 A IN 2014MN01420A
Authority
IN
India
Prior art keywords
cells
subpopulation
pbmcs
optionally
treatment
Prior art date
Application number
Inventor
Schwartz Michal Eisenbach
Ester Yoles
Ravid Shechter
Omer Miller
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IN2014MN01420A publication Critical patent/IN2014MN01420A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A subpopulation of peripheral blood mononuclear cells (PBMCs) that is substantially devoid of CD3+ cells CD19+ cells CD56+ cells and optionally of CD16+ cells for use in treatment of CNS injury is provided.
IN1420MUN2014 2011-12-14 2012-12-13 IN2014MN01420A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161570593P 2011-12-14 2011-12-14
PCT/IL2012/050522 WO2013088441A1 (en) 2011-12-14 2012-12-13 Human monocyte sub-population for treatment of central nervous system injury

Publications (1)

Publication Number Publication Date
IN2014MN01420A true IN2014MN01420A (en) 2015-04-03

Family

ID=48611950

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1420MUN2014 IN2014MN01420A (en) 2011-12-14 2012-12-13

Country Status (15)

Country Link
US (1) US9314483B2 (en)
EP (1) EP2790712B1 (en)
JP (1) JP6148679B2 (en)
KR (1) KR20140107439A (en)
CN (1) CN104159590A (en)
AU (2) AU2012354057B2 (en)
BR (1) BR112014014560A8 (en)
DK (1) DK2790712T3 (en)
ES (1) ES2604356T3 (en)
HU (1) HUE032096T2 (en)
IN (1) IN2014MN01420A (en)
MX (1) MX358589B (en)
PL (1) PL2790712T3 (en)
PT (1) PT2790712T (en)
WO (1) WO2013088441A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3226971B2 (en) 1992-08-04 2001-11-12 栗田工業株式会社 Water sampling and regeneration cycle controller for ion exchange equipment
ES2786253T3 (en) 2013-03-14 2020-10-09 Immusoft Corp Methods for the in vitro differentiation and transduction of memory b cells with pseudotyped viral vectors vsv-g
BR112015029299A2 (en) * 2013-05-22 2017-07-25 Yeda Res & Dev human monocyte subpopulation for treatment of eye diseases and disorders
EP4177336A1 (en) * 2014-12-19 2023-05-10 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
WO2017096246A1 (en) * 2015-12-03 2017-06-08 Temple University-Of The Commonwealth System Of Higher Education Modulation of nad+ and nad+ metabolic pathways for treatment of disease
US20220146534A1 (en) * 2019-01-16 2022-05-12 Yeda Research And Development, Co., Ltd. Biomarkers for CNS Disease Modification

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800812A (en) 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
WO1998005795A1 (en) * 1996-08-02 1998-02-12 The Center For Blood Research, Inc. Enrichment of dendritic cells from blood
US6267995B1 (en) 1999-03-03 2001-07-31 Pure World Botanicals, Inc. Extract of Lepidium meyenii roots for pharmaceutical applications
AU2002353465B2 (en) 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
JP2011515470A (en) * 2008-03-28 2011-05-19 ステムサイト インコーポレーテッド Treatment of brain injury with umbilical cord blood cells
BR112015029299A2 (en) * 2013-05-22 2017-07-25 Yeda Res & Dev human monocyte subpopulation for treatment of eye diseases and disorders

Also Published As

Publication number Publication date
HUE032096T2 (en) 2017-09-28
MX2014007188A (en) 2015-09-22
JP2015501835A (en) 2015-01-19
PT2790712T (en) 2016-12-02
KR20140107439A (en) 2014-09-04
ES2604356T3 (en) 2017-03-06
MX358589B (en) 2018-08-27
BR112014014560A8 (en) 2017-07-04
WO2013088441A1 (en) 2013-06-20
EP2790712B1 (en) 2016-08-31
EP2790712A1 (en) 2014-10-22
DK2790712T3 (en) 2016-12-19
AU2012354057A1 (en) 2014-07-31
PL2790712T3 (en) 2017-04-28
EP2790712A4 (en) 2015-06-24
US20140363411A1 (en) 2014-12-11
JP6148679B2 (en) 2017-06-14
US9314483B2 (en) 2016-04-19
CN104159590A (en) 2014-11-19
BR112014014560A2 (en) 2017-06-13
AU2012354057B2 (en) 2017-08-03
AU2017254830A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
IL282219B (en) Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
EP2879710A4 (en) AGENTS FOR MODULATING ACTIVATION OF IMMUNE CELLS AND METHODS OF USE THEREOF
MX382102B (en) Improved methods for manufacturing adoptive cell therapies
TN2013000468A1 (en) Use of anti-cd19 maytansinoid immunoconjugate antibody for the treatment of b-cell malignancies symptoms
EP2736543A4 (en) THERMOCONDUCTIVE METALLIC BANDAGES ACCELERATING HEALING AND METHODS OF USE
MX2009009283A (en) Engineered anti-il-23r antibodies.
MA34818B1 (en) ANTI-PCSK9 ANTIBODIES AND METHODS OF USE
EP2723851A4 (en) SELF-RENEWING ENDODERMAL PROGENITOR LINES GENERATED FROM HUMAN PLURIPOTENT STEM CELLS AND METHODS OF USE THEREOF
AU339269S (en) Multimedia converter
MY163057A (en) Means and methods for trating dlblcl
MX2014004696A (en) Array of disposable absorbent articles.
MX353302B (en) Treatment of pain associated with dislocation of basal endometrium.
IL276077A (en) Method of vitro fertilization with delivery of embryo transfer and use of peripheral blood mononuclear cells
GB201109238D0 (en) Antibodies
PL2736473T3 (en) An absorbent belted article wherein the belt and the absorbent pad have specific kinetic coefficients of friction
MX358589B (en) Human monocyte sub-population for treatment of central nervous system injury.
AU342071S (en) Large bowl
GB2510524A (en) Pulmonary hypertension
IN2015DN00172A (en)
MX2013012083A (en) Biomarkers for the treatment of multiple myeloma.
GB2497255A (en) Dice
UA48629U (en) method for enrichment of magnetically purified CD34 positive stem hematopoietic cells
UA70181U (en) Method for immunological evaluation of effectiveness of interferon therapy in patients with skin melanoma
GEU20131763Y (en) Phototherapeutic device "aisi 2"
CA143999S (en) Diaper pail